S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SRPT Sarepta Therapeutics Inc New

126.29

2.20 (1.77%)

04 Jan 2025 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics Inc New News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 1 January 2025 (5 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 31 December 2024 (5 days ago) • Edgar (US Regulatory)

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Thursday 19 December 2024 (3 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 13 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 7 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 6 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 30 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Saturday 30 November 2024 (1 month ago) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Saturday 30 November 2024 (1 month ago) • Business Wire

Form 8-K - Current report
Tuesday 26 November 2024 (1 month ago) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
Tuesday 26 November 2024 (1 month ago) • Business Wire

More Sarepta Therapeutics Inc New News Articles

Commonwealth Bank Of Aus...

Westpac Banking

Invesco QQQ Trust Series 1

Australia And New Zealan...

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions